Videos

Dr Anthony Hunter reviews the other three approved JAK inhibitors for treatment of myelofibrosis: ruxolitinib, fedratinib, and pacritinib.

Jeremy Abramson, MD, discusses what the findings from the phase 3 TRANSFORM study of lisocabtagene maraleucel mean for patients with relapsed large B-cell lymphoma.

Benjamin Garmezy, MD, discusses some of the ongoing challenges or disparities seen in the community oncologist setting related to clinical trials.

Experts on non–small cell lung cancer discuss the role of antibody-drug conjugates and review their mechanism of action.

A review of preclinical studies looking at TROP2 expression in patients with non–small cell lung cancer.

Mwanasha Merrill discusses results from a phase 2 study which evaluated PD-1 blockade post autologous stem cell transplantation with pembrolizumab in patients with peripheral T-cell lymphoma.

BCG-unresponsive NMIBC treatment aims to eradicate disease or prolong disease-free intervals, with radical cystectomy as gold standard; newer options like pembrolizumab and gemcitabine/docetaxel provide improved alternatives, though logistic challenges remain.

BCG-unresponsive non-muscle invasive bladder cancer risks invasive progression; providers should suspect disease based on any abnormalities in cystoscopy and cytology, not just voiding symptoms.

Joshua K. Sabari, MD, offers key takeaways on treating patients with EGFR+ non–small cell lung cancer, highlighting the safety profile.

Expert insights on the treatment of patients with non–small cell lung cancer positive for EGFR mutations and what the PAPILLON study seeks to address.

An expert on EGFR+ non–small cell lung cancer discusses factors that influence treatment decisions.

An overview of recent data from the MARIPOSA trial investigating amivantamab plus lazertinib in patients with EGFR-positive advanced lung cancer.

Joshua K. Sabari, MD, reviews clinical trial data from FLAURA2 on osimertinib plus chemotherapy in patients with EGFR-mutated advanced lung cancer.

A medical oncologist provides an overview of treatment options available for patients with EGFR+ non–small cell lung cancer.

Joshua K. Sabari, MD, reviews the patient profile of a 73-year-old patient with EGFR+ non–small cell lung cancer.

Francis P. Worden, MD, provides background on the COSMIC-311 study, highlighting the methods and design utilized.

Hussein Tawbi, MD, PhD, closes his discussion by sharing some clinical pearls for fellow oncologists treating patients with metastatic melanoma.

Hussein Tawbi, MD, PhD, explains that if a patient with metastatic melanoma and a BRAF mutation progresses after initial checkpoint inhibitors, either combination immunotherapy or MEK inhibitor therapy is considered, based on disease progression pace and pattern.

The SIMPLIFY-1 trial investigated the use of momelotinib in JAK inhibitor-naive patients with myelofibrosis, primarily symptomatic with spleen enlargement, hepatomegaly, or anemia; results showed momelotinib led to improved transfusion independence, reduced transfusion burden, and decreased anemia compared to ruxolitinib.

Anthony Hunter, MD, explains that anemia is a common complication in patients with myelofibrosis, often worsening over time; treatment strategies involve monitoring, transfusion support, and considering additional anemia-directed agents.

Mark Agulnik, MD, discusses advances in determining the molecular drivers of the tumor in the sarcoma space.

Mrinal M. Gounder, MD, delves into the data supporting the recent FDA approval of nirogacestat for the treatment of adult patients with desmoid tumors.

Liza C. Villaruz, MD, discusses what research in the EGFR-positive lung cancer space has recently caught the attention of experts.

Mohamad Adham Salkeni, MD, FRCPC, discusses the mechanism of action of ivaltinostat and what rationalizes its use in combination with capecitabine for patients with metastatic pancreatic adenocarcinoma.

Abdulraheem Yacoub, MD, closes by sharing that the myelofibrosis treatment landscape is expected to evolve in the coming years with results to come from clinical trials investigating combination therapies, novel agents, and targeted approaches for disease progression and improving durability of response.

Severe anemia in myelofibrosis is defined as hemoglobin under 8 g/dL or transfusion dependence, requiring management with JAK inhibitors, erythropoietin stimulating agents, or danazol, given its impact on patient prognosis.

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, provide an overview of TROP2 as a target for patients with non–small cell lung cancer.

Expert perspectives on unmet needs in the NSCLC treatment landscape and the role of antibody-drug conjugates in addressing them.

Domenech Asbun, MD, discusses first-, second-, and later lines of therapy for patients with gastrointestinal stromal tumor.

The phase 3 DREAMseq trial compared initial treatments of combination immunotherapy or BRAF/MEK inhibitors for B-Raf mutated melanoma, showing a 20% overall survival benefit at 2 years for immunotherapy as the first-line treatment.